Ferroptosis in Lupus: Can selenium help?
Official title: Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
Run by University Hospital, Bordeaux · NCT07260942 · Data updated 2026-11-12
This study tests whether iron-dependent cell death (ferroptosis) plays a role in lupus and whether selenium compounds can reduce ferroptosis in people with systemic lupus erythematosus.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 1 site (Bordeaux) |
| Status | Recruiting |
| Started | April 21, 2026 |
| Main results expected | April 2029 |
| Study ends | April 2029 |
| Registry record updated | May 18, 2026 |
| Trial ID | NCT07260942 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older with diagnosed systemic lupus erythematosus who consent to participate.
✕Probably not a fit
Patients without lupus or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers aim to measure lipid peroxidation and GPx4 expression in adults with SLE and examine whether selenium compounds can inhibit ferroptosis in immune cells. The study uses blood samples to assess biomarkers and the effect of GPx4-mimicking selenium compounds on ferroptosis triggered by P-selectin. It builds on prior animal and preliminary human data suggesting ferroptosis may worsen lupus and that selenium-based strategies could be therapeutic. The project is led by a Bordeaux team in collaboration with CHU de Bordeaux, focusing on translational insights for potential future therapies.
Why it matters
Potential benefit: If successful, the approach could identify a new pathway to modulate lupus activity and inform future therapeutic strategies.
How similar studies have gone: Evidence from mouse models and limited human data in other inflammatory diseases suggest ferroptosis is a relevant target, but translational human data in lupus are still emerging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years; * diagnosis of systemic lupus erythematosus; * being affiliated to health insurance, willing to participate and to sign informed consent; * control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease. Exclusion Criteria: * pregnant or breastfeeding women; * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Where it's running
-
CHU de Bordeaux - service de rhumatologie
Bordeaux, France Recruiting
Study contacts
- Principal investigator: Christophe RICHEZ, Prof — University Hospital, Bordeaux
- Study coordinator: Christophe RICHEZ, Prof
- Email: christophe.richez@chu-bordeaux.fr
- Phone: (0)5 56 79 55 56
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of anifrolumab on arterial inflammation in SLE patients
This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.
-
Home urine testing for people with lupus
Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
Biomarker tests in adults with lupus to see how kidney disease changes over time
Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.
-
Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia
This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.